Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) have received an average rating of “Buy” from the five analysts that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have covered the stock in the last year is $4.60.
A number of research firms recently issued reports on CLSD. StockNews.com downgraded shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Friday, May 10th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Clearside Biomedical in a research note on Tuesday, August 13th. Oppenheimer initiated coverage on Clearside Biomedical in a research report on Tuesday, June 25th. They issued an “outperform” rating and a $5.00 target price for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $4.00 price target on shares of Clearside Biomedical in a research note on Tuesday, August 13th.
Get Our Latest Analysis on Clearside Biomedical
Clearside Biomedical Stock Down 4.3 %
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.25 million. During the same quarter last year, the company earned ($0.15) EPS. As a group, research analysts expect that Clearside Biomedical will post -0.6 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in Clearside Biomedical during the first quarter worth about $49,000. International Assets Investment Management LLC bought a new stake in shares of Clearside Biomedical during the 1st quarter valued at about $57,000. XTX Topco Ltd grew its holdings in shares of Clearside Biomedical by 172.2% during the second quarter. XTX Topco Ltd now owns 54,313 shares of the company’s stock worth $71,000 after purchasing an additional 34,359 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Clearside Biomedical in the second quarter worth approximately $368,000. Finally, Renaissance Technologies LLC raised its stake in Clearside Biomedical by 6.6% in the second quarter. Renaissance Technologies LLC now owns 582,689 shares of the company’s stock valued at $757,000 after purchasing an additional 35,900 shares in the last quarter. Institutional investors own 18.75% of the company’s stock.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Read More
- Five stocks we like better than Clearside Biomedical
- What Are Dividend Achievers? An Introduction
- This Small Cap Wealth Management Stock Could Provide Big Returns
- How Can Investors Benefit From After-Hours Trading
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.